GEN Exclusives

More »

GEN News Highlights

More »
Sep 20, 2012

Alliance Aims to Push Boundaries for Bioseparation

  • Austrian firm BIA Separations and The Centre for Bio Separations Technology (CBST) at India’s VIT University are combining their expertise to develop new bioseparation platforms and technologies, and establish a BioSeparations Platform of Excellence at CBST, which will offer technical support, contract research, and services to the biopharmaceutical industry.

    CBST/VIT says teaming up with BIA will give it access to leading-edge technologies and expertise in the field of downstream purification and separation of large biomolecules, which will complement its own scientific and research capabilities to help bridge the gap between industry and academia in the bioseparations field. From the BIA perspective the partnership will not only bring benefits to the biopharmaceutical and academic sectors globally, but will also provide the firm with the opportunity to establish an Indian operation.

    CBST/VIT was established in 2005 by the Indian government as a center of excellence in bioseparation technologies, spearheading innovative research, with state-of-the-art technologies and multidisciplinary approaches, research, and training. The facility is focused primarily on therapeutics, and has specialist expertise protein expression, purification, and validation.

    A key goal of the center is to train Indian scientists and disseminate knowledge in the field of bioseparation technologies, which it claims is limiting factor in value-added biomolecules production. To this end CBST offers training in biomolecule production, including protein expression, monoclonal antibody production, and the production and purification of other bioactive molecules.

    BIA Separations manufactures the CIM Convective Interaction Media® short monolithic chromatographic columns, which are optimized for the separation and purification of large biomolecules and viral particles on a laboratory and industrial scale. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?